

# Neurology

|                     |                                    |                               | Phase 1 | Phase 2 | Phase 3 |
|---------------------|------------------------------------|-------------------------------|---------|---------|---------|
| <b>valbenazine*</b> | Dyskinetic Cerebral Palsy          | VMAT2 Inhibitor               |         |         |         |
| <b>NBI-827104§</b>  | Rare Pediatric Epilepsy: EE-CSWS   | Ca <sub>v</sub> 3.1, 3.2, 3.3 |         |         |         |
| <b>NBI-921352##</b> | Rare Pediatric Epilepsy: SCN8A-DEE | Na <sub>v</sub> 1.6           |         |         |         |
| <b>NBI-1076986</b>  | Movement Disorders                 | M4 Antagonist                 |         |         |         |

# Neuroendocrinology

|  |  |                  |  |  |  |
|--|--|------------------|--|--|--|
| <b>crinecerfont†</b>                   | Congenital Adrenal Hyperplasia in Adults                 | CRF <sub>1</sub> |  |  |  |
| <b>crinecerfont†</b>                   | Congenital Adrenal Hyperplasia in Children & Adolescents | CRF <sub>1</sub> |  |  |  |
| <b>modified-release hydrocortisone</b> | Adrenal Insufficiency                                    | GC Receptor      |  |  |  |
| <b>modified-release hydrocortisone</b> | Congenital Adrenal Hyperplasia                           | GC Receptor      |  |  |  |

# Neuropsychiatry

|                         |   |                       |  |  |  |
|-------------------------|---|-----------------------|--|--|--|
| <b>valbenazine*</b>     | Adjunctive Treatment of Schizophrenia                         | VMAT2 Inhibitor       |  |  |  |
| <b>NBI-1065845¶</b>     | Inadequate Response to Treatment in Major Depressive Disorder | AMPA                  |  |  |  |
| <b>luvadaxistat¶</b>    | Cognitive Impairment Associated with Schizophrenia            | DAAO                  |  |  |  |
| <b>NBI-1117568††</b>    | Schizophrenia   | M4 Agonist            |  |  |  |
| <b>NBI-1070770¶</b>     | Major Depressive Disorder                                     | NMDA NR2B NAM         |  |  |  |
| <b>NBI-1117570††</b>    | CNS Indications   | M1/M4 Agonist         |  |  |  |
| <b>NBI-1117569††</b>    | CNS Indications   | M4 Preferring Agonist |  |  |  |
| <b>NBI-1117567††,**</b> | CNS Indications   | M1 Preferring Agonist |  |  |  |
| <b>NBI-1065890</b>      | CNS Indications   | VMAT2 Inhibitor       |  |  |  |

EE-CSWS = Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep.  
 SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome.  
 Neurocrine Biosciences has global rights, unless otherwise noted.  
 Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

\* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.  
 § Licensed from Idorsia Ltd.  
 ## Licensed from Xenon Pharmaceuticals, Inc.

† Licensed from Sanofi.  
 ¶ Licensed from Takeda Pharmaceutical Company Limited.  
 †† Licensed from Nxera Pharma (formerly Sosei Heptares).

\*\* Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.